Physician profile
Barbara E Smith
NPI 1730187261
$161.97
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26.13 · 2020: $21.03 · 2021: $30.03 · 2022: $84.78.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $49.52 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $25.93 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $21.03 | 2020 | |
| Sanofi-Aventis U.S. LLC | $19.79 | 2022 | |
| Abbvie INC. | $16.38 | 2021 | |
| Glaxosmithkline, LLC. | $15.67 | 2022 | |
| Novo Nordisk INC | $13.65 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.